Physician profile
Emily A Fleming
NPI 1801624549
$900.69
in general payments reported to CMS, 2019-2025
14 companies · $609 in 2025
The $609 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $101 · 2024: $191 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $799.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $187.59 | 2024-2025 | Watchman Flx, Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $127.49 | 2024-2025 | Wainua, Farxiga |
| Scpharmaceuticals INC. | $112.17 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.80 | 2022 | |
| Pfizer INC. | $87.18 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $46.65 | 2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $46.49 | 2025 | |
| Amgen INC. | $43.37 | 2025 | Repatha |
| Regeneron Healthcare Solutions, INC. | $29.06 | 2025 | Evkeeza |
| Novo Nordisk INC | $27.91 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $27.90 | 2025 | Injectafer |
| Kiniksa Pharmaceuticals International, Plc | $26.76 | 2024 | Arcalyst |
| Cardiva Medical, INC. | $21.91 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Impulse Dynamics (USA) INC. | $15.41 | 2025 | Optimizer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.